Investors: Announcements

October 4, 2022

Notification of cessation of securities - AVH

September 30, 2022

Form 8-K Material terms of CEO's Employment Agreement

September 29, 2022

AVITA Medical Appoints James Corbett as CEO

September 20, 2022

Ceasing to be a substantial holder

September 20, 2022

AVITA Medical Investor Webinar Briefing Deck

September 14, 2022

Investor Webinar Briefing

September 13, 2022

Positive Trial Results Treating Stable Vitiligo With RECELL

September 9, 2022

Change of Director's Interest Notice - Michael Perry

September 9, 2022

Notice under section 708A(5)(e) of the Corporations Act

September 9, 2022

Notification regarding unquoted securities - AVH

September 7, 2022

Statement of CDIs on issue - AVH

September 7, 2022

Notification of cessation of securities - AVH

September 2, 2022

RECELL Insurance Coverage Begins in Japan for Acute Burns

August 30, 2022

AVITA Medical Corporate Deck August 2022

August 19, 2022

Notice under section 708A(5)(e) of the Corporations Act

August 19, 2022

Notification regarding unquoted securities - AVH

August 18, 2022

RECELL Presentations at Laser & Cosmetic Surgery Meeting

August 12, 2022

Half Year Financial Report Form 10-Q

August 12, 2022

AVITA Medical Topline Results from Soft-Tissue Pivotal Trial

August 12, 2022

AVITA Medical Reports Second Quarter 2022 Financial Results

August 5, 2022

Statement of CDIs on issue - AVH

August 3, 2022

Notification of cessation of securities - AVH

July 26, 2022

AVITA to Announce Second Quarter 2022 Financial Results

July 25, 2022

Notification regarding unquoted securities - AVH

July 22, 2022

Ceasing to be a substantial holder

July 11, 2022

Notification regarding unquoted securities - AVH

July 6, 2022

Statement of CDIs on issue - AVH

July 1, 2022

Notification of cessation of securities - AVH

June 10, 2022

Change of Director's Interest Notice - Michael Perry

June 10, 2022

Notice under section 708A(5)(e) of the Corporations Act

June 10, 2022

Notification regarding unquoted securities - AVH

June 7, 2022

Statement of CDIs on issue - AVH

June 3, 2022

Notification of cessation of securities - AVH

June 2, 2022

AVITA Medical Investor Webinar

May 13, 2022

Quarterly Financial Report (Form 10-Q)

May 12, 2022

AVITA Medical Corporate Presentation May 2022

May 10, 2022

RECELL System to be Presented at SCALE Dermatology Meeting

May 6, 2022

Statement of CDIs on issue - AVH

May 6, 2022

Final Director's Interest Notice - Louis Drapeau

May 6, 2022

Notification of cessation of securities - AVH

April 29, 2022

AVITA to Announce First Quarter 2022 Financial Results

April 22, 2022

AVH - Resignation of Louis Drapeau from Board of Directors

April 12, 2022

Notification regarding unquoted securities - AVH

April 8, 2022

Statement of CDIs on issue - AVH

April 7, 2022

Notification of cessation of securities - AVH

April 5, 2022

RECELL Data to be Presented at American Burn Assoc. Meeting

March 24, 2022

RECELL Vitiligo Protocol Presentation at Vitiligo Symposium

March 22, 2022

AVITA Medical Webinar Alert 11am (AEDT) 24 March 2022

March 22, 2022

AVITA Medical Announces Modification of BARDA Contract

March 10, 2022

Notification regarding unquoted securities - AVH

March 8, 2022

Cowen Conference Presentation

March 7, 2022

Statement of CDIs on issue - AVH

March 3, 2022

Notification of cessation of securities - AVH

March 3, 2022

Notice under section 708A(5)(e) of the Corporations Act

March 3, 2022

Change of Director's Interest Notice-Michael Perry

March 3, 2022

Notification regarding unquoted securities - AVH

March 3, 2022

AVITA Medical signs agreement with Premier Inc

March 1, 2022

Appendix 4G and Corporate Governance Statement

March 1, 2022

Financial Results December 21 Quarter and Transition Period

March 1, 2022

Appendix 4E and Preliminary Final Report (Form 10-K)

February 28, 2022

AVITA Medical Corporate Presentation

February 24, 2022

AVITA (AVH) Announces RECELL Receives Japan PMDA Approval

February 24, 2022

AVITA Medical to Present at Cowen Health Care Conference

February 18, 2022

AVITA - Approval of New RECELL System Improved Ease of Use

February 16, 2022

AVITA (AVH) Announces July 1- Dec 31, 2021 Financial Results

February 4, 2022

Statement of CDIs on issue - AVH

February 2, 2022

AVITA Medical to Present at the BTIG MedTech Conference

February 1, 2022

Notification of cessation of securities - AVH

January 25, 2022

Substantial Holder Notice

January 25, 2022

RECELL Data to be Presented at Annual Boswick Symposium

January 12, 2022

Notification regarding unquoted securities - AVH

January 12, 2022

Notification of cessation of securities - AVH

January 11, 2022

AVITA Medical Announces Preliminary Unaudited Results

January 7, 2022

Statement of CDIs on issue - AVH

January 7, 2022

AVITA Medical Completes Enrollment in Pivotal Trial

January 7, 2022

AVITA Medical Establishes Proof of Concept for Gene Therapy